GENAERA CORPORATION

Basic Information

ATTN: CHRIS SCHNITTKER
5110 CAMPUS DRIVE
PLYMOUTH MEETING, PA, 19462

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Aminosterols as Anti-angiogenic Therapeutics for AMD

    Amount: $100,000.00

    Age-related macular degeneration (AMD) is a public health problem resulting in the loss of independence in a significant number of the elderly population. The most severe form of AMD, wet AMD, is caus ...

    SBIR Phase I 2004 Department of Health and Human Services
  2. Aminosterol MSI-1436 as a Therapeutic for Obesity

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Obesity is a disease that has increased at an alarming rate. Today, 64.5 percent of adult Americans (about 127 million) are categorized as being overweight (body m ...

    SBIR Phase I 2004 Department of Health and Human Services
  3. AMINOSTEROL COMPOUNDS AS THERAPEUTIC FOR ASTHMA

    Amount: $0.00

    DESCRIPTION (provided by applicant):Phase II research will emphasize continuing in vitro and in vivo data collection to identify Genaera aminosterol library compounds useful in treating a ...

    SBIR Phase I 2002 Department of Health and Human Services
  4. AMINOSTEROL COMPOUNDS AS THERAPEUTIC FOR ASTHMA

    Amount: $796,186.00

    DESCRIPTION (provided by applicant):Phase II research will emphasize continuing in vitro and in vivo data collection to identify Genaera aminosterol library compounds useful in treating a ...

    SBIR Phase II 2002 Department of Health and Human Services
  5. N/A

    Amount: $100,000.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  6. MANUFACTURING DEVELOPMENT FOR SQUALAMINE LACTATE

    Amount: $105,610.00

    Not Available There exists a need within the military and civilian sectors for a system that marries the best qualities of an underwater SLR camera with a camcorder. The IEM system will possess the c ...

    SBIR Phase I 1999 Department of Health and Human Services
  7. NOVEL MAGAIN DRUGS FOR PSEUDOMEMBRANOUS COLITIS

    Amount: $500,000.00

    THE LONG-RANGE OBJECTIVES OF THIS PROJECT ARE TO (1) IDENTIFY NOVEL DRUG CANDIDATES RELATED TO THE MAGAININ CLASSOF PEPTIDES WITH POTENTIAL ANTIBACTERIAL, ANTIVIRAL, AND ANTI-INFLAMMATORY ACTIVITY THA ...

    SBIR Phase II 1991 Department of Health and Human Services
  8. MAGAININS' ROLE IN INHIBITING ORAL FLORA AND SYNERGY EFFECTS

    Amount: $50,000.00

    THE LONG-TERM OBJECTIVES OF THIS PROJECT ARE TO (1) IDENTIFYNOVEL DRUG CANDIDATES RELATED TO THE MAGAININ PEPTIDE CLASS WITH POWERFUL ANTI-INFECTIVE ACTIVITY AGAINST PATHOGENIC ORAL CAVITY FLORA, (2) ...

    SBIR Phase I 1990 Department of Health and Human Services
  9. NOVEL MAGAIN DRUGS FOR PSEUDOMEMBRANOUS COLITIS

    Amount: $50,000.00

    N/A

    SBIR Phase I 1989 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government